Breaking News

Anacor, Sandoz in KERYDIN Commercialization Pact

July 21, 2014

Companies enter long-term supply and profit-sharing arrangement

Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, under which Sandoz will distribute and commercialize Anacor’s KERYDIN (tavaborole) topical solution in the U.S. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for sales and marketing. The FDA approved the drug on July 8th for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed.
Anacor will receive $40 million upfront and an additional milestone payment of $25 million, expected in January 2015. The two companies have entered a long-term profit-sharing arrangement that includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45 million. Anacor also has the option to repurchase all rights to KERYDIN from Sandoz three years from launch or December 2017.
Anacor will supply product to Sandoz at cost through Anacor’s contract manufacturers, and Sandoz will be responsible for selling, marketing, distribution, and general and administrative costs related to commercialization. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.
“We are pleased to enter into this agreement with Sandoz to commercialize KERYDIN in the U.S. through PharmaDerm,” said Paul Berns, chief executive officer of Anacor. “PharmaDerm’s dedication to branded prescription products to treat dermatological and podiatric diseases makes it an ideal collaborator to launch KERYDIN. In addition, PharmaDerm has an experienced sales force which will be able to reach the specialty physicians who treat large numbers of patients with onychomycosis.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks